• 1
    Potosky AL, Miller BA, Albertsen PC, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995; 273: 548.
  • 2
    Cooperberg MR, Park S, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004; 22: 2141-2149.
  • 3
    Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360: 1320-1328.
  • 4
    Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360: 1310-1319; erratum 1797.
  • 5
    Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. JAMA. 1994; 271: 368.
  • 6
    Klotz L. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol. 2004; 172: S48-S50; discussion S50-S51.
  • 7
    Warlick C, Trock BJ, Landis P, et al. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst. 2006; 98: 355.
  • 8
    Dall'Era MA, Konety BR, Cowan JE, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008; 112: 2664-2670.
  • 9
    Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol. 2003; 170: 1792.
  • 10
    Steyerberg EW, Roobol MJ, Kattan MW, et al. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol. 2007; 177: 107.
  • 11
    Epstein JI, Chan DW, Sokoll LJ, et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol. 1998; 160( pt 2): 2407-2411.
  • 12
    Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006; 98: 529-534.
  • 13
    Nam RK, Toi A, Klotz LH, et al. Assessing individual risk for prostate cancer. J Clin Oncol. 2007; 25: 3582-3588.
  • 14
    Kawachi MH, Bahnson RR, Barry M, et al. NCCN. Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007; 5: 714-736.
  • 15
    Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer screening trends. J Natl Cancer Inst. 2002; 94: 981-990.
  • 16
    Zietman AL, Thakral H, Wilson L, Schellhammer P. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol. 2001; 166: 1702-1706.
  • 17
    Carter HB, Walsh PC, Landis P, et al. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol. 2002; 167: 1231-1234.
  • 18
    Carter CA, Donahue T, Sun L, et al. Temporary deferred therapy (watchful waiting) for men younger than 70 years with low-risk localized prostate cancer in the prostate specific antigen era. J Clin Oncol. 2003; 21: 4001-4008.
  • 19
    Patel MI, DeConcini DT, Lopez-Corona E, et al. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol. 2004; 171: 1520-1524.
  • 20
    Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med. 2008; 358: 1250-1261.
  • 21
    Carroll P, Albertsen PC, Greene K, et al. Prostate-Specific Antigen Best Practice Statement: 2009 Update. Linthicum, MD: American Urological Association Office of Education and Research; 2009.
  • 22
    Kapoor DA, Klimberg IW, Malek JH, et al. Single dose ciprofloxacin versus placebo for prophylaxis during transrectal ultrasound prostate biopsy. Urology. 1998; 52: 552-558.
  • 23
    Feliciano J, Teper E, Ferrandino M, et al. The incidence of flouroquinolone resistant infections after prostate biopsy—are flouroquinolones still effective prophylaxis? J Urol. 2008; 179: 952-955.
  • 24
    Ekwueme DU, Stroud LA, Chen Y. Cost analysis for screening, diagnosing and staging prostate cancer based on a systematic review of published studies. Prev Chron Dis. 2007; 4: A100.
  • 25
    Dong F, Kattan MW, Steyerberg EW, et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol. 2008; 180: 150-154.
  • 26
    Nam RK, Toi A, Trachtenberg J, et al. Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy. J Urol. 2006; 175: 489-494.
  • 27
    Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Euro Urol. 2010; 57: 79-85.
  • 28
    Benson MC, Olsson CA. Prostate specific antigen and prostate specific antigen density: roles in patient evaluation and treatment. Cancer. 1994; 74: 1667-1673.
  • 29
    Bretton PR, Evans WP, Borden JD, et al. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma. Cancer. 1994; 74: 2991-2995.
  • 30
    Seaman EK, Wang IS, Cooner W, et al. Predictive value of prostate specific antigen density for the presence of micrometastatic carcinoma of the prostate. Urology. 1994; 43: 645-648.
  • 31
    Brassell SA, Tzu-Cheg K, Sun L, et al. Prostate specific antigen versus prostate specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology. 2005; 66: 1229-1233.
  • 32
    Naya Y, Slaton JW, Troncoso P, Okihara K, Babaian RJ. Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension. J Urol. 2004; 171: 1093-1097.